Notably, antibodies targeting cytotoxic T lymphocyte antigen‐4 (CTLA‐4) and programmed cell death protein 1 (PD‐1) emerged as superior prognostic markers for HCC patient responses. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.